P Gibbs
Overview
Explore the profile of P Gibbs including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
180
Citations
2154
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Andre T, Shiu K, Kim T, Jensen B, Jensen L, Punt C, et al.
Ann Oncol
. 2024 Dec;
36(3):277-284.
PMID: 39631622
Background: Results from the phase III KEYNOTE-177 study established pembrolizumab as a new first-line standard of care for microsatellite instability-high or mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC). Previous results...
2.
Jalali A, Smith S, Kim G, Wong H, Lee M, Yeung J, et al.
Cancer Treat Res Commun
. 2024 Jun;
40:100827.
PMID: 38885543
Background: Colorectal cancer (CRC) incidence and mortality rates have been increasing among young patients (YP), for uncertain reasons. It is unclear whether YP have a distinct tumor biology or merit...
3.
Gately L, Mesia C, Sepulveda J, Del Barco S, Pineda E, Girones R, et al.
J Neurooncol
. 2024 Apr;
168(2):299-306.
PMID: 38630385
Purpose: The impact of age on optimal management of glioblastoma remains unclear. A recent combined analysis of two randomised trials, GEINO14-01 and EX-TEM, found no benefit from extending post-radiation temozolomide...
4.
Gately L, Mesia C, Sepulveda J, Del Barco S, Pineda E, Girones R, et al.
J Neurooncol
. 2024 Jan;
166(3):417-418.
PMID: 38289531
No abstract available.
5.
Gately L, Mesia C, Sepulveda J, Del Barco S, Pineda E, Girones R, et al.
J Neurooncol
. 2023 Dec;
166(3):407-415.
PMID: 38153582
Purpose: The optimal duration of post-radiation temozolomide in newly diagnosed glioblastoma remains unclear, with no published phase III randomised trials. Standard-of-care stipulates 6 months. However, in routine care, it is...
6.
Silva A, Greensmith M, Praseedom R, Jah A, Huguet E, Harper S, et al.
Surgeon
. 2022 Feb;
20(5):e288-e295.
PMID: 35144899
Background: Surgical resection, where appropriate, remains one of the best treatment options for hepatocellular carcinoma (HCC), however outcomes can be compromised by the development of liver failure. We reviewed our...
7.
Jalali A, Gard G, Banks S, Dunn C, Wong H, Wong R, et al.
Curr Probl Cancer
. 2021 Sep;
46(2):100793.
PMID: 34565601
For patients with refractory metastatic colorectal cancer (mCRC) treatment with Trifluridine/Tipiracil, also known as TAS-102, improves overall survival. This study aims to investigate the efficacy and safety of TAS-102 in...
8.
Romeo V, Clauser P, Rasul S, Kapetas P, Gibbs P, Baltzer P, et al.
Eur J Nucl Med Mol Imaging
. 2021 Aug;
49(2):596-608.
PMID: 34374796
Purpose: To assess whether a radiomics and machine learning (ML) model combining quantitative parameters and radiomics features extracted from simultaneous multiparametric F-FDG PET/MRI can discriminate between benign and malignant breast...
9.
Conduit C, de Boer R, Lok S, Gibbs P, Malik L, Loh Z, et al.
Asia Pac J Clin Oncol
. 2020 Aug;
16(6):356-362.
PMID: 32779390
Background: Anti-HER2 therapy-related cardiotoxicity is well described in the context of clinical trials, particularly in the setting of early stage disease, but there is more limited data in advanced breast...
10.
Jones N, Burnett C, Salamon S, Landers J, Wende H, Lazzarini L, et al.
J Mater Chem B
. 2020 Apr;
6(22):3665-3673.
PMID: 32254829
Iron oxide nanoparticles (IONs) are being actively researched and experimented with as contrast agents for Magnetic Resonance Imaging (MRI), as well as image-directed delivery of therapeutics. The efficiency of an...